Lifitegrast Ophthalmic Solution 5%

Introduction Overview

Generic Name

lifitegrast ophthalmic solution 5%

Brand Name

Xiidra

Dosage Form

Eye drops

Drug Class

Ophthalmic anti-inflammatory agents

Pharmacokinetics

Absorption:

Xiidra (lifitegrast ophthalmic solution 5%) is administered as a topical ophthalmic solution, and thus systemic absorption is minimal. The drug acts locally in ocular tissues with negligible systemic bioavailability. Studies have shown that systemic exposure after ocular instillation is very low, reducing the likelihood of systemic side effects or interactions. The drug is designed for direct application onto the ocular surface, where it can exert its pharmacologic effects on the ocular tissues involved in dry eye disease.

Distribution:

Due to its topical ophthalmic administration and minimal systemic absorption, lifitegrast primarily remains localized in the ocular surface and conjunctival tissues. The drug targets inflammatory pathways within the cornea and conjunctiva, which are primary sites of dry eye disease-related inflammation. The formulation permits retention on the ocular surface, with adequate penetration to reach the conjunctival and corneal cells where the inflammatory cascade occurs. The specific partitioning into ocular tissues allows lifitegrast to exert localized pharmacological action without extensive systemic distribution.

Metabolism:

There is limited data on systemic or ocular metabolism of lifitegrast due to its topical ocular administration and low systemic exposure. It is presumed that any lifitegrast absorbed systemically would undergo hepatic metabolism via usual catabolic pathways for small molecules but this is not well characterized or clinically significant. On the eye surface, lifitegrast does not undergo enzymatic modification that impacts its activity significantly, allowing it to retain its functional integrity at the site of inflammation.

Elimination:

Elimination of lifitegrast occurs primarily through tear film drainage and normal ocular surface turnover. The small volume drops are rapidly cleared through the nasolacrimal duct to the nasal mucosa and then swallowed, where any absorbed drug would be subject to gastrointestinal metabolism and elimination. The design of single-use vials helps maintain sterile application and avoid accumulation or contamination. Systemic elimination pathways are minor given negligible systemic exposure. The local ocular clearance is mainly through tear drainage and blinking mechanisms.

Dosage Forms

Available Dosage Forms:

Xiidra is provided as ophthalmic solution eye drops containing 5% lifitegrast (50 mg/mL). It is supplied in single-use 0.2 mL low-density polyethylene containers. These single-use containers are grouped in foil pouches, each containing 5 containers, and cartons hold 12 such foil pouches, totaling 60 single-dose containers.

Dosages for Adults and Adolescents:

The recommended dosage for adults aged 17 years and older is one drop instilled in each eye twice daily approximately 12 hours apart. Consistent administration every 12 hours optimizes therapeutic levels on the ocular surface and maintains symptom relief.

Specific Patient Populations:

Xiidra is approved only for use in individuals 17 years of age and older. Safety and efficacy in pediatric patients younger than 17 years have not been established. There is limited information regarding use during pregnancy and lactation; thus, consultation with a healthcare provider is advised. Contact lens wearers should remove lenses prior to administration and wait at least 15 minutes before reinsertion. No adjustment of dosage is currently recommended for elderly patients or those with renal or hepatic impairment due to negligible systemic absorption.

Mechanism Of Action

Lifitegrast, the active component of Xiidra, serves as a selective antagonist of the integrin lymphocyte function-associated antigen-1 (LFA-1) on the surface of T lymphocytes. LFA-1 binds to its natural ligand, intercellular adhesion molecule-1 (ICAM-1), which is overexpressed in ocular surface tissues in dry eye disease. This binding promotes T-cell activation, migration, and infiltration into the conjunctiva and cornea, driving inflammation.

By blocking the LFA-1/ICAM-1 interaction, lifitegrast inhibits T-cell adhesion, activation, and subsequent release of pro-inflammatory cytokines such as interleukin-1 (IL-1), tumor necrosis factor alpha (TNF-α), and interferon gamma (IFN-γ). This dampening of the inflammatory cascade reduces ocular surface inflammation, thereby alleviating symptoms such as dryness, irritation, and discomfort associated with dry eye disease.

Cellular pathways influenced by lifitegrast include the downregulation of T-cell-mediated immune responses localized in corneal and conjunctival epithelium, resulting in decreased recruitment and activation of inflammatory cells. Lifitegrast’s biochemical prescription targets the immune-mediated component of dry eye disease rather than only symptomatic relief. Clinical trials have demonstrated significant improvement in both signs (e.g., corneal staining) and symptoms (e.g., dry eye symptoms assessments) with lifitegrast treatment.

Compared with cyclosporine ophthalmic solutions (e.g., Restasis), which inhibit calcineurin and broadly suppress T-cell activity, lifitegrast acts upstream by directly blocking lymphocyte adhesion and activation. This selective mechanism may offer a rapid onset of action and a distinct side effect profile. Ongoing research continues to evaluate the long-term benefits and safety of lifitegrast in chronic ocular surface inflammation.

Pharmacological Actions

Selective antagonist of LFA-1 integrin, inhibiting binding to ICAM-1.
Blocks T-cell activation, adhesion, and migration on ocular surface tissues.
Suppresses secretion of inflammatory cytokines such as IL-1, TNF-α, and IFN-γ.
Reduces ocular surface inflammation associated with dry eye disease.
Improves tear film stability and ocular surface integrity indirectly via anti-inflammatory effects.
Targets the immune-mediated component of dry eye pathophysiology.
Demonstrates anti-inflammatory effects localized to conjunctival and corneal epithelium.
Reduces signs like corneal staining and symptoms such as discomfort and dryness.
Acts upstream in the inflammatory cascade distinct from calcineurin inhibitors.
Provides a twice-daily dosing regimen for sustained therapeutic effect.
Minimally absorbed systemically, limiting systemic immunosuppression risks.

Therapeutic Or Clinical Uses

Treatment of signs and symptoms of dry eye disease (DED) in adults aged 17 and older.
Management of chronic inflammatory ocular surface conditions contributing to dry eye.
Reduction of ocular surface inflammation mediated by T-cell activation.
Improvement of tear film quality and ocular surface comfort in dry eye patients.
Alleviation of ocular discomfort, burning, and irritation associated with DED.
Adjunct treatment in patients inadequately managed by artificial tears alone.
Non-steroidal therapy option to avoid corticosteroid-related complications.
Alternative or complementary therapy to cyclosporine ophthalmic solutions.
Prescribed for patients with moderate to severe dry eye symptoms.
An option for patients requiring sustained anti-inflammatory ocular therapy.
Used in adult patients including elderly populations with dry eye disease.
Supports management of dry eye signs such as corneal epithelial staining.

Side Or Adverse Effects

Blurred vision immediately following administration.
Eye discomfort including burning or stinging sensation.
Eye irritation or redness reported by some patients.
Unusual or unpleasant taste sensation (dysgeusia) after administration.
Potential for allergic reactions including hives, swelling, or difficulty breathing.
Severe eye redness or irritation necessitating discontinuation.
Rare reports of vision problems requiring prompt medical attention.
Minimal systemic side effects due to low systemic absorption.
Transient ocular irritation generally resolves with continued use.
No significant reports of systemic immunosuppression-related adverse effects.
Non-preservative formulation reduces risk of preservative-related ocular toxicity.
Rare localized hypersensitivity reactions possible.
No evidence of gastrointestinal or other systemic adverse effects.
Safety profile well-characterized in clinical trials up to 12 months.
Discontinuation advised if severe ocular reactions occur.

Precautions

Use caution if patient is concurrently using other ophthalmic medications; wait at least 10 minutes between drops.
Remove contact lenses prior to administration; wait 15 minutes before reinsertion.
Inform healthcare provider if pregnant, planning pregnancy, or breastfeeding due to insufficient safety data.
Avoid touching the eye dropper tip to the eye or any surface to prevent contamination.
Store single-use vials in original sealed foil pouch until use to maintain drug integrity.
Do not use in patients under 17 years old as safety and efficacy are not established.
Consult physician before use if eye infection or allergic conjunctivitis is present.
Monitor for signs of ocular irritation or worsening of symptoms during therapy.
Follow exact dosing schedule; do not use in larger doses or more frequently than prescribed.
Patients with a history of hypersensitivity to lifitegrast or formulation components should avoid use.
Proper hygiene recommended before application to minimize infection risk.
Use with caution if the patient has a history of severe ocular surface disease.
Discontinue and seek medical advice if vision changes or severe eye irritation develops.
Ensure patients understand single-use dosing vial disposal to prevent accidental reuse.
Advise patients about the potential for temporary taste disturbances post-instillation.

Warnings

No absolute contraindications have been identified for Xiidra use.
Risk of allergic reactions including anaphylaxis though rare; seek immediate medical attention if symptoms occur.
Avoid contamination of the eye dropper tip to prevent serious eye infections.
Do not exceed recommended dosing frequency to prevent ocular surface toxicity.
Safety during pregnancy and lactation has not been established; weigh risks versus benefits.
Patients should not combine Xiidra with other dry eye prescription drops unless directed by a healthcare provider.
Use with caution in patients with preexisting severe eye irritation or infection.
Monitor for severe eye redness or pain that may signal adverse reaction or secondary infection.
Not studied for use in pediatric population under 17 years; safety unknown.
Use with caution in patients who have had prior ocular surgeries until healing is complete.
Prolonged use beyond recommended period should be under medical supervision.
Potential for transient visual disturbance immediately after administration.
Avoid use if container foil pouch is punctured or damaged to ensure sterility.
Follow up regularly with healthcare provider for assessment of treatment effectiveness and ocular health.
Patients should report any sudden decreases in vision promptly.

Contraindication

Known hypersensitivity to lifitegrast or any inactive ingredients in the formulation.
Avoid use if there is a history of allergic reaction to ophthalmic solutions with similar components.
No other specific contraindications have been identified as of current clinical evidence.
Use contraindicated if sterility of single-use vial is compromised.
Not recommended in patients younger than 17 years old due to lack of data.
Contraindicated if patient has active ocular infection until treated appropriately.
Avoid in patients with history of severe eye inflammation unrelated to dry eye disease.
Use contraindicated if any signs of chemical sensitivity or ocular toxicity occur.
Do not use in combination with other topical ophthalmic anti-inflammatory agents without medical advice.
Contraindicated in patients unable to comply with administration and storage instructions to mitigate infection risk.
Patients with sensitivity to preservatives should note Xiidra is preservative-free; hypersensitivity to formulation agents must be ruled out.
Discontinue use if unexpected systemic or ocular allergic reactions develop.
Caution advised in polypharmacy due to unknown compounded hypersensitivity risks.

Drug Interactions

No significant drug-drug interactions have been reported with Xiidra due to minimal systemic absorption.
Potential physical incompatibility if mixed with other ophthalmic solutions; separate dosing by at least 10 minutes.
Concurrent use with other topical ocular medications should be spaced to avoid washout and optimize absorption.
No known interactions with systemic drugs including immunosuppressants or anti-inflammatory agents.
No evidence of interactions affecting effectiveness of oral or systemic medications.
No interaction data reported for use with contact lens disinfecting solutions; lenses must be removed prior to use.
No contraindication with artificial tears; timing of administration should be managed to optimize efficacy.
No reported interactions with common systemic medications such as anticoagulants, antihypertensives, or antibiotics.
No observed impact on cytochrome P450 enzymes due to localized application and low systemic levels.
No documented interaction with dietary supplements or herbal products.
Potential additive local irritation if combined with multiple ophthalmic agents causing ocular surface dryness or toxicity.
Patients should inform healthcare providers about all topical and systemic medications prior to starting Xiidra.
No requirement to adjust concomitant systemic drug therapy when initiating or discontinuing Xiidra.
No known interaction with vaccines or immunomodulatory medications used systemically.
Further post-marketing surveillance continues to monitor for any emerging interaction reports.

Preparations Of The Drug

Lifitegrast ophthalmic solution 5% (50 mg/mL) formulated as a sterile aqueous solution.
Packaged in preservative-free, single-use low-density polyethylene (LDPE) containers of 0.2 mL volume.
Each carton contains 12 foil pouches; each pouch holds 5 single-use containers (total 60 doses/pack).
Includes inactive ingredients such as sodium chloride, sodium phosphate dibasic anhydrous, sodium thiosulfate pentahydrate, sodium hydroxide and/or hydrochloric acid for pH adjustment, and water for injection.
Foil pouches maintain sterility and protect individual vials from light and moisture.
Single-use design intended to prevent contamination and ensure dose accuracy.
Vials are transparent, allowing visual verification of solution clarity before administration.
Supplied and manufactured by Bausch + Lomb Pharmaceuticals.
Stored at controlled room temperature (20–25°C / 68–77°F) protected from excessive heat, moisture, and light.
Requires patient education for proper handling and disposal of single-use vials after each administration.
No preservatives included to reduce the risk of preservative-induced ocular surface toxicity.
Packaging includes clear labeling with instructions on use and disposal to promote safety and compliance.
Designed to provide ease of use with a small droplet volume suitable for ocular administration.
Accompanied by patient information leaflets detailing storage, administration, and safety precautions.
Packaging materials are compatible with the formulation to maintain stability throughout shelf life.